April 1, 2019
Lupin names new Independet Director
Pharma player Lupin Limited has appointed Christine Mundkur as an Independent Director with immediate effect, the company said Monday, recent CEO of Impopharma Inc.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Asia
April 1, 2019
Shionogi Announces Submission of Cefiderocol Marketing Authorisation Application
OSAKA, Japan & AMSTERDAM, NL–(BUSINESS WIRE)–Shionogi & Co., Ltd (hereafter “Shionogi”) announces that the Marketing Authorisation Application (MAA) submission for…
April 1, 2019
EMA Accepts Takeda’s MAA for Subcutaneous Formulation of Vedolizumab for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis and Crohn’s Disease
Additional treatment modality would provide greater choice in how patients receive gut-selective biologic vedolizumab Vedolizumab set to be the only…
March 27, 2019
Dr. Reddy’s Laboratories launches Tadalafil Tablets USP in the U.S. Market
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together…
March 27, 2019
IGC Provides Corporate Updates
BETHESDA, Md.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/Hyalolex?src=hash” target=”_blank”gt;#Hyalolexlt;/agt;–India Globalization Capital, Inc. (NYSE:IGC) announces today that, as of Wednesday, March 27, 2019, Hyalolex™, the…
March 22, 2019
Cerveau Technologies Inc. Signs Research Agreement with Eisai Inc., for Novel Tau Imaging Agent
BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s…
March 22, 2019
Eisai, Biogen kick-off phase 3 testing early Alzheimer’s disease antibody, amid dropping aducanunab trial. Eisai’s US company presents AD pipeline
Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.
March 22, 2019
LegoChem Biosciences and Takeda Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates in Immuno-Oncology
– Takeda obtains rights to LCB’s ADC platfo–LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080) announced today that it has entered a research…
March 21, 2019
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class…
March 21, 2019
Alvogen’s Taiwan company – Lotus – exchange stake with Fuji Pharma
@alvogenpr subsidiary in Taiwan, Lotus Pharmaceuticals today announced capital and business collaboration agreements with Fuji Pharma in Japan, as Fuji has acquired a 2.0% stake in Lotus for approximately US$20 million (or NT$ 617 million, JPY 2.2 billion). Lotus has also acquired 3.9% stake in Fuji for an equal sum.